<DOC>
	<DOCNO>NCT02884206</DOCNO>
	<brief_summary>The purpose study evaluate effect LCZ696 compare valsartan cognitive function patient heart failure preserve ejection fraction . Cognitive function assess use comprehensive battery test evaluation longitudinal change cognitive domain include memory , executive function , attention .</brief_summary>
	<brief_title>Efficacy Safety LCZ696 Compared Valsartan Cognitive Function Patients With Heart Failure Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Key Chronic heart failure current symptom NYHA class IIIV Left ventricular ejection fraction &gt; 40 % echo Patients least one following : Patient heart failure hospitalization 12 month prior screen visit NTproBNP &gt; 200 pg/mL screen Patient evidence adequate functioning complete study assessment Key Patients acute decompensated heart failure require augment therapy diuretic , vasodilator and/or inotropic drug Acute coronary syndrome ( include myocardial infarction ( MI ) ) , cardiac surgery , major CV surgery , urgent percutaneous coronary intervention ( PCI ) , carotid surgery carotid angioplasty , history stroke transient ischemic attack within 3 month prior Screening visit elective PCI within 30 day prior Screening visit Patients history hereditary idiopathic angioedema angioedema relate previous ACEi ARB therapies Patients require treatment 2 following : ACEi , ARB renin inhibitor Patients one following : 1 . Patients serum potassium &gt; 5.2 mmol/L ( mEq/L ) Screening visit 2 . Patients serum potassium &gt; 5.4 mmol/L ( mEq/L ) visit runin treatment period randomization visit 3 . Systolic blood pressure ( SBP ) ≥180 mmHg Screening visit , 4 . SBP &lt; 110 mmHg Screening visit , 5 . SBP &lt; 100 mmHg symptomatic hypotension determine investigator Visit 103 randomization visit 6 . Body mass index ( BMI ) &gt; 40 kg/m^2 Patients 1. know pericardial constriction , genetic hypertrophic cardiomyopathy , infiltrative cardiomyopathy 2. history dilate cardiomyopathy , include peripartum cardiomyopathy , chemotherapy induce cardiomyopathy , viral myocarditis Lifethreatening uncontrolled dysrhythmia , include symptomatic sustain ventricular tachycardia atrial fibrillation flutter rest ventricular rate &gt; 110 beat per minute Inability perform cognitive battery study evaluation base significant motor ( e.g . hemiplegia , muscularskeletal injury ) sensory ( blindness , decrease uncorrected visual auditory acuity ) skill According MRI central reader , MRI evidence : 1 . &gt; 2 lacunar infarct large cortical subcortical infarct &gt; 1cm^3 2. white matter lesion correspond overall Fazekas score 3 require least 1 confluent hyperintense lesion FLAIR sequence , ≥20 mm dimension 3 . Clinically significant cerebral pathology example large cerebral aneurysm space occupy lesion 4 . ≥4 micro hemorrhage see gradient echo image Mini mental state examination score le 24 screening</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart failure</keyword>
	<keyword>cognition</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>LCZ696</keyword>
	<keyword>valsartan</keyword>
</DOC>